Heavy chain constant regions with reduced binding to Fc gamma receptors

Patent metadata

Field	Value
Publication number	US-12509516-B2
Application number	US-202217961442-A
Country	US
Kind code	B2
Filing date	Oct 6, 2022
Priority date	Mar 30, 2015
Publication date	Dec 30, 2025
Grant date	Dec 30, 2025

Abstract

The invention provides antibody heavy chain constant regions with a hinge region modified to reduce binding to Fcγ receptors. The modification occurs within positions 233-236 by replacement of natural residues by glycine(s) and/or deletion(s). Such modifications can reduce binding of an antibody bearing such a constant region to Fcγ receptors to background levels. The constant regions can be incorporated into any format of antibody or Fc fusion protein. Such antibodies or fusion proteins can be used in methods of treatment, particularly those in which the mechanisms of action of the antibody or Fc fusion protein is not primarily or at all dependent on effector functions, as is the case when an antibody inhibits a receptor-ligand interaction or agonizes a receptor.

First claim

What is claimed is:

1 . A bispecific antibody comprising:
a first heavy chain duplexed with a light chain, wherein the heavy chain comprises a heavy chain variable region and a heavy chain constant region that is human IgG1, IgG2, or IgG4 isotype, wherein amino acid positions 233-236 of a hinge domain are G, G, G and unoccupied; G, G, unoccupied, and unoccupied; G, unoccupied, unoccupied, and unoccupied; or all unoccupied, with amino acid positions numbered by EU numbering, and the light chain comprises a light chain variable region and a light chain constant region, and wherein the heavy chain variable region and the light chain variable region form a first antigen-binding domain that binds a target antigen; and a second heavy chain duplexed with a light chain, wherein the heavy chain comprises a heavy chain variable region and a heavy chain constant region that is human IgG1, IgG2, or IgG4 isotype, wherein amino acid positions 233-236 of a hinge domain are G, G, G and unoccupied; G, G, unoccupied, and unoccupied; G, unoccupied, unoccupied, and unoccupied; or all unoccupied, with amino acid positions numbered by EU numbering, and the light chain comprises a light chain variable region and a light chain constant region, and wherein the heavy chain variable region and the light chain variable region form a second antigen-binding domain that binds an antigen on an effector cell.

2 . The bispecific antibody of claim 1 , wherein the target antigen is an antigen on a cancer cell.

3 . The bispecific antibody of claim 1 , wherein the target antigen is an antigen on a pathogen.

4 . The bispecific antibody of claim 1 , wherein the antigen on the effector cell is CD3.

5 . The bispecific antibody of claim 1 , wherein the first heavy chain the second heavy chain are of isotype IgG4.

6 . The bispecific antibody of claim 5 , wherein: the first heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 5, and the second heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 9; or the first heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 9, and the second heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 5.

7 . The bispecific antibody of claim 5 , wherein: the first heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 6, and the second heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 10; or the first heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 10, and the second heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 6.

8 . The bispecific antibody of claim 5 , wherein: the first heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 7, and the second heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 11; or the first heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 11, and the second heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 7.

9 . The bispecific antibody of claim 5 , wherein: the first heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 8, and the second heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 12; or the first heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 12, and the second heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 8.

10 . The bispecific antibody of claim 1 , wherein the first heavy chain the second heavy chain are of isotype IgG1.

11 . The bispecific antibody of claim 10 , wherein: the first heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 16, and the second heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 20; or the first heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 20, and the second heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 16.

12 . The bispecific antibody of claim 10 , wherein: the first heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 17, and the second heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 21; or the first heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 21, and the second heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 17.

13 . The bispecific antibody of claim 10 , wherein: the first heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 18, and the second heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 22; or the first heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 22, and the second heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 18.

14 . The bispecific antibody of claim 10 , wherein: the first heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 19, and the second heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 23; or the first heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 23, and the second heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 19.

15 . The bispecific antibody of claim 1 , wherein the first heavy chain the second heavy chain are of isotype IgG2.

16 . The bispecific antibody of claim 15 , wherein: the first heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 24, and the second heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 28; or the first heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 28, and the second heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 24.

17 . The bispecific antibody of claim 15 , wherein: the first heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 25, and the second heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 29; or the first heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 29, and the second heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 25.

18 . The bispecific antibody of claim 15 , wherein: the first heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 26, and the second heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 30; or the first heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 30, and the second heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 26.

19 . The bispecific antibody of claim 15 , wherein: the first heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 27, and the second heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 31; or the first heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 31, and the second heavy chain comprises a heavy chain constant region comprising SEQ ID NO: 27.

Assignees

• Regeneron Pharma

Inventors

• Davis Samuel
• Smith Eric
• Zhang Tong
• Patel Supriya

Classifications

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title

• C07K2317/526

  CH3 domain · CPC title

• C07K2317/90

  characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin · CPC title

• C07K16/2803 Primary

  against the immunoglobulin superfamily · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title